Defining and recognising locally advanced basal cell carcinoma
- PMID: 26574792
- DOI: 10.1684/ejd.2015.2641
Defining and recognising locally advanced basal cell carcinoma
Abstract
Background: Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term "locally advanced BCC" (laBCC). We identified and described the diverse settings that could be considered "locally advanced".
Methods: The panel of experts included oncodermatologists, dermatological and maxillofacial surgeons, pathologists, radiotherapists and geriatricians. During a 1-day workshop session, an interactive flow/sequence of questions and inputs was debated.
Results: Discussion of nine cases permitted us to approach consensus concerning what constitutes laBCC. The expert panel retained three major components for the complete assessment of laBCC cases: factors of complexity related to the tumour itself, factors related to the operability and the technical procedure, and factors related to the patient. Competing risks of death should be precisely identified. To ensure homogeneous multidisciplinary team (MDT) decisions in different clinical settings, the panel aimed to develop a practical tool based on the three components.
Conclusion: The grid presented is not a definitive tool, but rather, it is a method for analysing the complexity of laBCC.
Keywords: basal cell carcinoma; definition; locally advanced.
Similar articles
-
Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study.J Am Acad Dermatol. 2016 Nov;75(5):957-966.e2. doi: 10.1016/j.jaad.2016.06.020. Epub 2016 Jul 26. J Am Acad Dermatol. 2016. PMID: 27473450
-
Current treatment options for locally advanced and metastatic basal cell carcinoma. A narrative review.Expert Rev Anticancer Ther. 2025 Jun;25(6):621-632. doi: 10.1080/14737140.2025.2498999. Epub 2025 Apr 29. Expert Rev Anticancer Ther. 2025. PMID: 40296667 Review.
-
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6. Eur J Cancer. 2019. PMID: 31288208 Review.
-
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.Future Oncol. 2015;11(4):703-12. doi: 10.2217/fon.14.281. Future Oncol. 2015. PMID: 25686123 Review.
-
Updates in Management of Locally and Regionally Advanced Basal Cell Carcinoma.Surg Clin North Am. 2025 Jun;105(3):629-638. doi: 10.1016/j.suc.2024.11.012. Epub 2025 Jan 27. Surg Clin North Am. 2025. PMID: 40412890 Review.
Cited by
-
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.Target Oncol. 2019 Jun;14(3):253-267. doi: 10.1007/s11523-019-00648-2. Target Oncol. 2019. PMID: 31243642 Review.
-
Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.Drug Des Devel Ther. 2022 Jan 14;16:183-190. doi: 10.2147/DDDT.S325852. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35058688 Free PMC article. Review.
-
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.Oncotarget. 2021 Sep 28;12(20):2089-2100. doi: 10.18632/oncotarget.28080. eCollection 2021 Sep 28. Oncotarget. 2021. PMID: 34611482 Free PMC article. Review.
-
Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.Int J Mol Sci. 2024 Jun 27;25(13):7056. doi: 10.3390/ijms25137056. Int J Mol Sci. 2024. PMID: 39000164 Free PMC article. Review.
-
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. Epub 2019 Dec 8. Br J Dermatol. 2020. PMID: 31545507 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical